Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sarilumab + prednisone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a **combination of sarilumab and prednisone**, typically used in the management of polymyalgia rheumatica and potentially other inflammatory diseases. - **Sarilumab** is a fully human monoclonal antibody that acts as an interleukin-6 (IL-6) receptor antagonist, blocking both soluble and membrane-bound IL-6 receptors and thereby reducing inflammation. - **Prednisone** is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant agent. The combination is investigated primarily to manage patients with polymyalgia rheumatica who have relapsed during attempts to taper off glucocorticoids; sarilumab enables more successful steroid tapering and remission maintenance by targeting the proinflammatory cytokine IL-6, while prednisone provides rapid anti-inflammatory benefits and disease control during the transition[1][2][3][4][6][7].
- Other names
- sarilumab + prednisone
02
Targets
GR (Glucocorticoid receptor)IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on sarilumab + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sarilumab + prednisone.